Free tool
FAERS Monitor: Qutenza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022395 or its brand name (Qutenza, Capsaicin). Reports on generic versions are filed under their own applications.
Reports
3,257
Serious
1,865
57% of reports
Hospitalization
610
Death reported
156
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- application site pain607
- pain424
- drug ineffective377
- burning sensation330
- pain in extremity215
- application site erythema165
- fatigue159
- off label use145
- insomnia110
- dyspnoea105
- paraesthesia100
- weight increased100
- nausea96
- hypoaesthesia91
- dizziness86
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 16 |
| 2005 | 24 |
| 2006 | 21 |
| 2007 | 23 |
| 2008 | 6 |
| 2009 | 13 |
| 2010 | 17 |
| 2011 | 44 |
| 2012 | 86 |
| 2013 | 78 |
| 2014 | 117 |
| 2015 | 105 |
| 2016 | 133 |
| 2017 | 114 |
| 2018 | 137 |
| 2019 | 173 |
| 2020 | 130 |
| 2021 | 183 |
| 2022 | 197 |
| 2023 | 250 |
| 2024 | 326 |
| 2025 | 724 |
| 2026 | 340 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,902 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site painSignal | 607 | 183.0 | 170.1 | 106,757 |
| application site erythemaSignal | 165 | 40.9 | 35.2 | 6,351 |
| burning sensationSignal | 330 | 30.5 | 27.6 | 9,384 |
| pain in extremitySignal | 215 | 4.7 | 4.1 | 634 |
| painSignal | 424 | 4.5 | 4.1 | 1,168 |
| paraesthesiaSignal | 100 | 4.1 | 3.4 | 234 |
| hypoaesthesiaSignal | 91 | 3.9 | 3.2 | 197 |
| weight increasedSignal | 100 | 2.9 | 2.4 | 122 |
| insomniaSignal | 110 | 2.7 | 2.2 | 114 |
| drug ineffective | 377 | 1.8 | 1.7 | 155 |
| fatigue | 159 | 1.3 | 1.1 | 12 |
| dyspnoea | 105 | 1.2 | 1.0 | 3 |
| dizziness | 86 | 1.1 | 0.9 | 1 |
| off label use | 145 | 1.1 | 0.9 | 1 |
| nausea | 96 | 0.8 | 0.6 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.